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14-3-3z regulates the mitochondrial respiratory
reserve linked to platelet phosphatidylserine
exposure and procoagulant function
Simone M. Schoenwaelder1,2,3,*, Roxane Darbousset1,2,3,*, Susan L. Cranmer3,*, Hayley S. Ramshaw4,*,
Stephanie L. Orive3, Sharelle Sturgeon3, Yuping Yuan1,2,3, Yu Yao3, James R. Krycer2,5, Joanna Woodcock4,
Jessica Maclean1,2,3, Stuart Pitson4, Zhaohua Zheng3, Darren C. Henstridge6, Dianne van der Wal3,
Elizabeth E. Gardiner3,7, Michael C. Berndt8, Robert K. Andrews3, David E. James2,5,9, Angel F. Lopez4
& Shaun P. Jackson1,2,3,10
The 14-3-3 family of adaptor proteins regulate diverse cellular functions including cell
proliferation, metabolism, adhesion and apoptosis. Platelets express numerous 14-3-3
isoforms, including 14-3-3z, which has previously been implicated in regulating GPIba
function. Here we show an important role for 14-3-3z in regulating arterial thrombosis.
Interestingly, this thrombosis defect is not related to alterations in von Willebrand factor
(VWF)–GPIb adhesive function or platelet activation, but instead associated with reduced
platelet phosphatidylserine (PS) exposure and procoagulant function. Decreased PS exposure
in 14-3-3z-deﬁcient platelets is associated with more sustained levels of metabolic ATP and
increased mitochondrial respiratory reserve, independent of alterations in cytosolic calcium
ﬂux. Reduced platelet PS exposure in 14-3-3z-deﬁcient mice does not increase bleeding risk,
but results in decreased thrombin generation and protection from pulmonary embolism,
leading to prolonged survival. Our studies deﬁne an important role for 14-3-3z in regulating
platelet bioenergetics, leading to decreased platelet PS exposure and procoagulant function.
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T
he 14-3-3 family of adaptor proteins are ubiquitously
expressed in eukaryotic cells and were the ﬁrst identiﬁed
phosphoserine- and phosphothreonine-binding proteins.
They interact with a wide variety of intracellular molecules,
including signalling proteins, metabolic enzymes, cytoskeletal
proteins, transcription factors, apoptosis regulators and tumour
suppressor proteins1,2. Consequently, they play a key role
in regulating cell cycle progression, apoptosis, metabolism, intra-
cellular trafﬁcking and in the regulation of cell stress responses1,3.
Seven 14-3-3 isoforms have been identiﬁed in mammalian
cells: b, e, z, g, Z, t and s. These isoforms associate as
homodimers or heterodimers to form a negatively charged
channel that constitutes a highly conserved ligand-binding
pocket. The 14-3-3 molecules can bind more than 200 different
proteins, with each 14-3-3 isoform showing a distinct preference
for selected proteins. The interaction with 14-3-3 can have a
major effect on target protein function, altering their localization,
stability, conformation and/or phosphorylation4.
14-3-3 proteins have been extensively investigated in nucleated
cells, however these proteins are also expressed in high levels in
anucleate cells including platelets, raising the possibility of
additional roles unrelated to gene transcription and proliferation.
Six 14-3-3 isoforms have been detected in human platelets
including b, e, z, g, Z and t, with z and g expressed at high levels.
The ﬁrst identiﬁed 14-3-3 binding partner in platelets was the
VWF receptor GPIb/V/IX, an adhesive molecule with a key role
mediating platelet–vessel wall and platelet–platelet adhesion
under conditions of high shear stress5–7. 14-3-3z binds to the
cytoplasmic tails of GPIba and GPIbb (ref. 8) and numerous
studies have focussed on the functional relevance of this
interaction for platelet activation and signalling. Some studies
have suggested that the GPIb-14-3-3z interaction can promote
VWF-dependent integrin aIIbb3-activation and cell spreading9,10,
whereas others have proposed a negative signalling role11,12.
It has been suggested that 14-3-3z binding to GPIba might
regulate the ligand binding function of the receptor13, although
several other studies have found no role for the 14-3-3z binding
domain of GPIba in regulating GPIba adhesive function9,14–17.
Understanding the role of the GPIb-14-3-3z interaction in
regulating platelet adhesion and activation is complicated by
the ﬁnding that all known isoforms of 14-3-3 in platelets can bind
to the cytoplasmic tail of GPIba (ref. 18), making interpretation
of the role of a single 14-3-3 isoform difﬁcult.
In the current study, we have investigated the importance of
14-3-3z in regulating platelet function by studying mice
genetically deﬁcient in this 14-3-3 isoform19. These studies have
uncovered a non-redundant role for 14-3-3z in regulating the
prothrombotic function of platelets in vivo. Interestingly, this
thrombosis defect is not due to abnormal VWF–GPIb adhesive
function, nor defective platelet activation induced by soluble
platelet agonists, but rather, through reduced platelet PS exposure
and procoagulant function. This defect in procoagulant function
in 14-3-3z-deﬁcient mice is associated with reduced arterial
thrombosis, as well as reduced thrombin generation and
pulmonary embolism in vivo. Analysis of platelet bioenergetics
has revealed enhanced mitochondrial respiratory reserve capacity
in 14-3-3z-deﬁcient platelets that correlated with sustained levels
of metabolic ATP. These studies identify 14-3-3z as an important
regulator of platelet bioenergetic function, linked to platelet
procoagulant function and thrombosis in vivo. Targeting platelet
metabolic pathways may represent a new approach to
antithrombotic therapy.
Results
14-3-3f-deﬁcient mice are protected from arterial thrombosis.
To investigate the importance of 14-3-3z in promoting
thrombosis in vivo, we utilized mice in which the 14-3-3z gene
(Ywhaz) had been knocked out globally using Lexicon gene trap
vector technology, as described previously19. We initially
compared the ability of these mice, referred to herein as
14-3-3z-deﬁcient mice, and matched 14-3-3z litter mate
controls to form occlusive arterial thrombi following electrolytic
injury to carotid arteries20. Electrolytic injury initiates the
formation of platelet-rich thrombi that typically occlude the
artery within 15–20 min (ref. 20). Analysis of carotid blood ﬂow
following injury revealed a signiﬁcant decrease in the ability of
14-3-3z-deﬁcient mice to form occlusive thrombi (Fig. 1a–e), with
stable vessel occlusion occurring in 80% of 14-3-3z-wild-type (wt)
mice compared with 20% of 14-3-3z-deﬁcient mice (Fig. 1e).
Consistent with this, vessel patency time in 14-3-3z-deﬁcient
mice wasB5-fold longer than for 14-3-3z-wt mice (Fig. 1c), and
time to initial vascular occlusion was signiﬁcantly delayed in
14-3-3z-deﬁcient mice (Fig. 1d). These studies suggest an
important role for 14-3-3z in regulating arterial thrombus
formation in mice.
14-3-3 proteins are ubiquitously expressed, therefore studies
were performed on a cohort of bone marrow transplanted mice to
conﬁrm that the thrombosis defect was related to deﬁciency of
14-3-3z in hemopoietic cells, rather than loss of 14-3-3z function
in the vessel wall. Four independent cohorts of bone marrow-
transplanted mice were generated, either on a 14-3-3z-wt or
14-3-3z-deﬁcient background, and transplanted with either
14-3-3z-wt or 14-3-3z-deﬁcient bone marrow. Mice from each
cohort were challenged with electrolytic injury and carotid blood
ﬂow monitored for the formation of an occlusive thrombus.
As demonstrated in Fig. 2a–d, the data obtained from these
cohorts recapitulated the observations with pure 14-3-3z-wt or
14-3-3z-deﬁcient mice (Fig. 1). Time to initial occlusion and
vessel patency time was signiﬁcantly increased in mice receiving
14-3-3z-deﬁcient bone marrow relative to mice transplanted with
14-3-3z-wt bone marrow, regardless of genetic background
(Fig. 2c,d). These studies conﬁrm that 14-3-3z expression in
hematopoietic cells (most likely platelets) is important for
vascular occlusion by arterial thrombi. In control studies, a slight
reduction in the circulating platelet count was observed in
14-3-3z-deﬁcient mice (14-3-3z-wt mean¼ 1,108±57; 14-3-3z-
deﬁcient mean¼ 963±39), however this was not sufﬁcient to
cause a thrombosis defect in mice21. This mild decrease in the
platelet count was unlikely to be due to increased platelet
apoptosis and clearance as the lifespan of 14-3-3z-deﬁcient
platelets was identical to 14-3-3z-wt controls (Supplementary
Fig. 1a). In further control studies, we conﬁrmed that there was
no altered expression of the major platelet surface receptors on
the surface of 14-3-3z-wt versus 14-3-3z-deﬁcient platelets
(Supplementary Fig. 1b).
To examine whether deﬁciency of 14-3-3z results in a
bleeding phenotype, we examined the haemostatic response in
14-3-3z-deﬁcient and 14-3-3z-wt mice following surgical
resection of the mouse tail22. Examination of bleeding time
using a 3mm tail lop revealed minimal impact on the haemostatic
response (Fig. 2e), with a non-signiﬁcant increase in the time to
cessation of bleeding. Furthermore, there was no evidence of
spontaneous or surgical bleeding in any of the mice examined.
Overall, these studies suggest an important role for 14-3-3z in
regulating the prothrombotic function of platelets, yet is
functionally redundant for the platelet haemostatic response.
Normal activation and adhesion in 14-3-3f-deﬁcient platelets.
To gain insight into the mechanisms by which 14-3-3z regulates
thrombus formation in vivo, we performed in vitro
ﬂow studies on a ﬁbrillar Type I collagen substrate using
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anticoagulated whole blood. The dynamics of platelet adhesion
and aggregation were examined in real-time and revealed no
major differences in thrombus formation between 14-3-3z-wt and
14-3-3z-deﬁcient mice (Fig. 3a). Moreover, VWF binding to
GPIba (Fig. 3b), VWF–GPIba-mediated platelet aggregation
(Fig. 3c) and platelet adhesion to immobilized VWF
(Supplementary Fig. 2a) was normal in mouse platelets deﬁcient
in 14-3-3z. Similarly, integrin aIIbb3-dependent platelet aggrega-
tion (Fig. 3d; Supplementary Fig. 2b) and agonist-induced platelet
activation (P-selectin expression and integrin aIIbb3 activation,
Fig. 3e,f), were also unperturbed in 14-3-3z-deﬁcient
platelets, or human platelets pretreated with a 14-3-3 dimer
destabilizer23 (Supplementary Fig. 3a,b). Multiple 14-3-3 isoforms
are expressed in platelets (Fig. 3g), all of which can associate
with GPIba (ref. 18). In control studies, we conﬁrmed by
immunoprecipitation and immunoblot analysis that 14-3-3z
associates with GPIba in 14-3-3z-wt platelet lysates (Fig. 3h).
We also conﬁrmed the loss of 14-3-3z in 14-3-3z-deﬁcient
platelet lysates by immunoblot analysis (Fig. 3g). To determine
the extent of 14-3-3 binding to GPIba in 14-3-3z-deﬁcient
platelets, GPIba was immunoprecipitated from whole-cell platelet
lysates and the immunoprecipitates blotted with a pan-14-3-3
polyclonal antibody (Fig. 3i). Similar levels of 14-3-3 binding to
GPIba was observed in 14-3-3z-wt and 14-3-3z-deﬁcient
platelets, suggesting that other 14-3-3 isoforms compensate for
the loss of 14-3-3z.
Reduced procoagulant function in 14-3-3f-deﬁcient platelets.
An important function of activated platelets is their ability to
support the assembly of coagulation complexes on their plasma
membrane, a process requiring PS exposure necessary for loca-
lized a-thrombin generation and ﬁbrin formation. Both thrombin
stimulation of platelets and ﬁbrin generation are important for
thrombus growth and stability, and as a consequence, drugs that
target thrombin’s actions inhibit arterial thrombus growth24. To
examine whether platelet procoagulant function was affected in
14-3-3z-deﬁcient mice, we examined exposure of PS on the
surface of thrombin and collagen-related peptide (CRP)-
stimulated platelets. This agonist combination induces high,
sustained cytosolic calcium ﬂux and platelet PS exposure through
a cell death pathway linked to mitochondrial-regulated cell
necrosis25,26. In response to co-stimulation with thrombin/CRP,
the ability of 14-3-3z-deﬁcient platelets to externalize PS, as
detected through Alexa 488-labelled Annexin V-binding, was
signiﬁcantly impaired (Fig. 4a), with an identical reduction
observed using FITC-lactadherin as an alternative probe for PS.
Similarly, pre-treating human (Fig. 4b) or 14-3-3z-wt mouse
platelets (Fig. 4c) with a 14-3-3 dimer destabilizer (RB-011)23
resulted in a speciﬁc defect in agonist-induced PS exposure. A
similar reduction in the development of procoagulant platelets
was apparent in RB-011-treated platelets adherent to an
immobilized collagen substrate under ﬂow conditions
(Supplementary Fig. 3c). Consistent with a reduction in PS
a
































































































































































Figure 1 | 14-3-3f deﬁciency reveals defective arterial thrombosis after electrolytic injury. (a–d) Electrolytic injury was induced in the carotid artery
of 14-3-3z-wt (black symbols/bars) or 14-3-3z-deﬁcient (14-3-3z-null, white symbols/bars) mice, as described under ‘Methods’. Carotid artery blood
ﬂow was monitored for 60min following arterial injury (injuryþ stasis) (a), and further analysed ofﬂine. Total blood ﬂow (b), time of vessel patency (c) and
time to initial occlusion (d) were quantiﬁed over a 60min period. Note: where vessels did not occlude, vessel patency was recorded as 60min. Results
reﬂect mean±s.e.m. (n¼ 5), with results analysed using an unpaired student t-test (**Po0.01, ***Po0.001). (e) The effect of 14-3-3z deﬁciency on
stability of blood ﬂow post injury was classiﬁed into three categories, as described under ‘Methods’.
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externalization, platelet-dependent ﬁbrin clot formation was also
reduced in both human platelets treated with RB-011 (Fig. 4d), as
well as platelets isolated from 14-3-3z-deﬁcient mice (Fig. 4e). In
control studies, we conﬁrmed that the effects of
RB-011 were selective for platelet procoagulant function,
as agonist-induced a-granule release (P-selectin expression) and
integrin aIIbb3 activation were normal in RB-011-treated platelets
(Supplementary Fig. 3a,b). Interestingly, RB-011 had minimal
effects on platelet PS exposure (Fig. 4c) and ﬁbrin clot formation
in 14-3-3z-deﬁcient platelets (Fig. 4f), indicating that 14-3-3z is
likely to be the main 14-3-3 isoform regulating platelet PS exposure.
PS exposure also occurs during platelet apoptosis, via an
activation-independent event linked to the Bcl-2 protein family26.
However, PS surface expression was normal in 14-3-3z deﬁcient
platelets treated with the pro-apoptotic BH3 mimetic, ABT-737
(Supplementary Fig. 4a). Moreover, PS exposure in platelets
treated with the calcium ionophore A23187 (Supplementary
Fig. 4b), which bypasses receptor signalling mechanisms linked to
calcium ﬂux, was normal in 14-3-3z-wt and 14-3-3z-deﬁcient
platelets. These ﬁndings indicate that the role of 14-3-3z is
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Figure 2 | Hematopoietic-speciﬁc 14-3-3f deﬁciency results in defective arterial thrombosis. (a–d) Electrolytic injury was induced in the carotid artery of
four cohorts of bone marrow-transplanted mice (refer to key): 14-3-3z-wt donor bone marrow (BM) into 14-3-3z-wt (n¼ 9) or 14-3-3z-null (n¼ 8)
recipient mice and 14-3-3z-null donor BM into either 14-3-3z-wt (n¼ 9) or 14-3-3z-null (n¼ 7) recipients, as described in ‘Methods’. Carotid artery blood
ﬂow over 60min (a), as well as total blood ﬂow (b), time of vessel patency (c) and time to initial occlusion (d) were quantiﬁed over 60min, as described in
the legend to Fig. 1. Results represent mean±s.e.m. (*Po0.05), where results were analysed using a one-way ANOVA with Sidaks post hoc testing.
(e) Haemostasis was examined using a 3mm tail lop model of bleeding time, as described under ‘Methods’. Results are expressed as time taken to bleeding
cessation, and represent the mean±s.e.m. (14-3-3z-wt, n¼ 11; 14-3-3z-null, n¼ 7). Results were analysed using an unpaired Student’s t-test (NSP40.05).
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14-3-3f-deﬁcient mice have reduced thrombin generation in vivo.
To investigate whether the alterations in platelet PS exposure
and procoagulant function in vitro reduced thrombin
generation in vivo, we performed studies in a collagen/
epinephrine pulmonary embolism model, a thrombosis model
that is both platelet- and coagulation-dependent27,28. Mice were
intravenously injected with collagen/epinephrine (1.0mg kg 1;
60 mg kg 1) or an equivalent volume of sterile saline, and blood
samples were taken to quantify thrombin generation. Seventy-ﬁve
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injection, compared with 12.5% of 14-3-3z-deﬁcient mice
(Fig. 5a). Histological examination of lung tissue demonstrated
that the majority of pulmonary vessels in wt mice were
completely occluded, whereas 14-3-3z-deﬁcient mice
demonstrated a signiﬁcant reduction in occlusive pulmonary
thromboemboli (Fig. 5b) and a marked decrease in thrombus
burden (Fig. 5b(ii)). ELISA-based quantiﬁcation of thrombin
generation, by measuring thrombin–antithrombin III complexes
(TAT), revealed signiﬁcantly lower levels of TAT in 14-3-3z-
deﬁcient mice at both 10 and 30min post challenge (Fig. 5c),
despite a similar drop in platelet count in 14-3-3z-deﬁcient mice
relative to 14-3-3z-wt mice (Fig. 5d). These ﬁndings are
consistent with the possibility that reduced thrombin
generation, rather than impaired platelet activation by collagen
and epinephrine, is primarily responsible for reduced thrombus
formation in 14-3-3z-deﬁcient mice.
Sustained metabolic ATP levels in 14-3-3f-deﬁcient platelets.
Agonist-induced platelet PS exposure and procoagulant function
are principally induced by opening of the mitochondrial perme-
ability transition pore, as a consequence of high, sustained levels
of cytosolic calcium29. Such high levels of sustained calcium are
toxic for the cell, leading to a speciﬁc form of cell death termed
regulated cell necrosis26,30,31. To investigate whether there were
differences in agonist-stimulated cytosolic calcium response
between 14-3-3z-wt and 14-3-3z-deﬁcient platelets, that might
explain the differences in the extent of PS exposure, washed
platelets were loaded with the calcium indicator dyes, Oregon-
Green BAPTA and Fura-Red, prior to platelet stimulation. These
studies revealed no signiﬁcant difference in cytosolic calcium ﬂux
in response to platelet stimulation by a broad range of agonists,
including thrombin and CRP (Supplementary Fig. 5).
Next, we considered the possibility that 14-3-3z may regulate
the metabolic function of platelets, since a major feature of
necrotic cell death is bioenergetic failure30. Quantitative analysis
of metabolic ATP in activated platelets revealed that potent
platelet stimulation with thrombin/CRP caused an B50%
depletion of metabolic ATP after 30min of stimulation in wt
platelets (Fig. 6a). In contrast, 14-3-3z-deﬁcient platelets
demonstrated sustained level of metabolic ATP, with o10%
reduction in ATP 30min post-stimulation with thrombin/CRP
(Fig. 6a). Consistent with this, human platelets pretreated with
RB-011 also demonstrated more sustained levels of metabolic
ATP following agonist challenge (Supplementary Fig. 6a). The
phosphorylation status of AMP kinase (AMPK) is a reliable
indicator of metabolic stress, with increased phosphorylation
coinciding with ATP depletion32. Consistent with the possibility
of reduced metabolic stress in 14-3-3z-deﬁcient platelets, AMPK
phosphorylation was reduced in 14-3-3z-deﬁcient platelets
relative to 14-3-3z-wt controls, following thrombin/CRP
stimulation (Fig. 6b,c). Taken together, these ﬁndings suggest
an important role for 14-3-3z in regulating the metabolic function
of platelets.
Elevated mitochondrial respiratory reserve in 14-3-3f-deﬁcient
platelets. The preservation of cellular ATP is achieved principally
through mitochondrial and glycolytic pathways33,34. 14-3-3z is
known to regulate the enzyme activity of two rate-limiting
glycolytic enzymes, 6-phosphofructokinase (6-PFK) and pyruvate
kinase (PK). We examined the glycolytic capacity of 14-3-3z-wt
and 14-3-3z-deﬁcient platelets by measuring proton ﬂux
(extracellular acidiﬁcation rate, ECAR) in the presence of
glutamine. Using an XFp extracellular ﬂux analyser (Seahorse
Bioscience), the glycolytic rate was determined by quantifying
ECAR in resting platelets, before and after exposure to glucose
(10mM). Maximum glycolytic capacity was determined by
treating platelets with the F0F1 ATP synthase inhibitor
Oligomycin A, and the contribution of the glycolytic pathway
was conﬁrmed by inhibiting glycolysis with 2-deoxyglucose
(2-DG). In both resting and thrombin/CRP-stimulated platelets,
ECAR measurements were identical in 14-3-3z-wt and 14-3-3z-
deﬁcient platelets under all experimental conditions tested
(Supplementary Fig. 7a,b), indicating that dysregulated
glycolysis was not a prominent feature of 14-3-3z-deﬁcient
platelets. Consistent with this, measurement of 6-PFK and PK
activity in lysates generated from resting and stimulated platelets
revealed no differences in the kinetics of both enzymes
(Supplementary Fig. 7c,d), suggesting that the alterations in
metabolic ATP in 14-3-3z-deﬁcient platelets were not primarily
due to alterations in glycolysis.
14-3-3z has been demonstrated to regulate mitochondrial
ATP generation in plant cells, by modifying the activity of
mitochondrial complex V (F0F1 ATP synthase)35,36. To examine
a potential contribution of mitochondria in the observed
14-3-3z-deﬁcient phenotype, platelets from 14-3-3z-wt or
14-3-3z-deﬁcient mice were incubated with the F0F1 ATP
synthase inhibitor, oligomycin A. As demonstrated in Fig. 7,
pre-treatment with oligomycin ablated the difference in agonist-
stimulated PS exposure between wt and 14-3-3z-deﬁcient
platelets (Fig. 7a). Consistent with this, oligomycin-pre-
Figure 3 | GPIba and platelet function are unperturbed by 14-3-3f deﬁciency. (a) Hirudin-anticoagulated blood from 14-3-3z-wt and 14-3-3z-deﬁcient
(14-3-3z-null) mice was perfused through collagen-coated (250mgml 1 Type I) microslides at 1,800 s 1 for 5min. (i) DIC images are taken from 1
representative of four independent experiments (scale bar, 20mm). (ii) Thrombi surface coverage was quantiﬁed using ImageJ software (4–5 ﬁelds
analysed per ﬂow). The histogram depicts the mean±s.e.m. (n¼ 5; analysed using two-way ANOVA with Bonferroni’s post hoc testing). (b) VWF binding
was measured as described under ‘Methods’. The graph represents one of three independent experiments. (c) Aggregation of washed mouse platelets in
the presence of human VWF (10 mgml 1) and botrocetin (10mgml 1), with stirring. The graph depicts aggregation traces from one representative of three
independent experiments. (d) Comparative aggregation of washed 14-3-3z-wt and 14-3-3z-null platelets in response to CRP or ADP ((i) ADP 1 mM; (ii) CRP
20ngml 1). Results are taken from one representative experiment. A histogram depicting the mean±s.e.m. (n¼ 3; analysed using a two-way ANOVA
with Bonferroni’s post hoc testing), is presented in Supplementary Fig. 2b. (e,f) Diluted whole blood samples from 14-3-3z-wt (black bars) or 14-3-3z-null
(white bars) mice were incubated with PE-JON/A (e) or FITC-anti P-selectin antibody (f), as described under ‘Methods’, to examine integrin aIIbb3 and
degranulation of platelet a-granules, respectively, and analysed by ﬂow cytometry, following incubation with the indicated agonist/concentration for 15min.
Results depict the % of gated platelets positive for antibody binding and are expressed as the mean±s.e.m. ((e) PAR4P: n¼ 10; CRP: n¼ 3; ADP: n¼4;
(f) PAR4P: n¼ 10; CRP: n¼ 5), where NSP40.05. Note: no signiﬁcant difference was observed in the geometric mean of ﬂuorescence intensity for the same
experiments. (g–i) Resting whole cell lysates were prepared from 14-3-3z-wt (wt) and 14-3-3z-null (null) washed platelets. (g) Expression levels of 14-3-3
isoforms were compared using SDS–PAGE and immunoblot analysis, as described under ‘Methods’, with immunoblots probed with the indicated 14-3-3
isoform-selective or pan-14-3-3 antibodies. These studies conﬁrm deletion of 14-3-3z protein in the 14-3-3z-null mice, with some upregulation of 14-3-3g.
(h,i) Association of 14-3-3 proteins with the GPIba cytoplasmic tail in the absence of 14-3-3z—GPIba was immunoprecipitated from 14-3-3z-wt and
14-3-3z-null platelet lysates as described under ‘Methods’, and analysed via immunoblotting, using (h) anti-14-3-3z or (i) anti-pan-14-3-3. Immunoblots are
taken from one representative of three independent experiments.
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Figure 4 | Reduced PS exposure and thrombin generation in 14-3-3f-deﬁcient platelets. (a–c) PS exposure was quantiﬁed in anticoagulated whole blood
isolated from 14-3-3z-wt or 14-3-3z-null mice (a), or in washed platelets isolated from either 14-3-3z-wt and 14-3-3z-null mice (c) or healthy human
donors (b). Where indicated, washed platelets were treated with a 14-3-3 dimer destabilizer (RB-011, 10mM) or vehicle (sodium mesylate salt), prior to
activation. In whole blood, PS exposure was quantiﬁed following stimulation of platelets with buffer (resting), CRP/Thrombin (CRP (0.25 mgml 1)/Thr
(0.5Uml 1)) or calcium ionophore A23187 (Iono, 1 mm), for the indicated times. Washed platelets were stimulated with CRP (0.25mgml 1)/TRAP (1mM)
or CRP (0.25mgml 1)/PAR4 activating peptide (200mM) (for human and mouse platelets, respectively) for the indicated times. PS was detected through
measurement of Alexa-488-labelled Annexin V binding (ANVþve), as described under ‘Methods’. Results are expressed as the mean±s.e.m. (n¼8),
where ****Po0.0001; ***Po0.001; **Po0.01; *Po0.05; NSP40.05. (d–f) Procoagulant function of washed human (d) or mouse platelets (e,f) was
examined using a modiﬁed aPTTassay with Ellagic acid as a soluble activator, as described under ‘Methods’. Resting platelets or those activated for 10min
with CRP/TRAP (d) or CRP/PAR4-activating peptide (e,f) were added as a source of phospholipid. Results depict the mean±s.e.m. (n¼4; where
****Po0.0001; ***Po0.001; **Po0.01; *Po0.05; NSP40.05). Results represent the aPTT in vehicle- and RB-011-treated activated platelets, relative to
resting platelets (d), the fold difference in aPTT when comparing activated vehicle- and RB-011-treated human (d, inset) or 14-3-3z-wt and 14-3-3z-null
mouse platelets (f), or the fold difference in aPTTwhen comparing activated 14-3-3z-wt and 14-3-3z-null mouse platelets (e). Where appropriate, results
were analysed using either unpaired Student’s t-test, one-way or two-way ANOVA (with Tukey’s or Bonferroni’s post hoc testing).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12862 ARTICLE
NATURE COMMUNICATIONS | 7:12862 | DOI: 10.1038/ncomms12862 | www.nature.com/naturecommunications 7
treatment also negated the sustained metabolic ATP levels
observed in 14-3-3z-deﬁcient platelets (Fig. 6a). Moreover,
while 14-3-3z-deﬁcient platelets were able to maintain
mitochondrial membrane potential (Dcm) following potent
stimulation when compared with their wt counterparts,
oligomycin pre-treatment also rendered both platelet genotypes
equally sensitive to mitochondrial membrane depolarization
(decreased Dcm) (Fig. 7b). These studies demonstrate that
inhibition of mitochondrial function through direct blockade of
the F0F1 ATP synthase negates the impact of 14-3-3z deﬁciency
on platelet bioenergetics, PS exposure and Dcm, indicating that
altered mitochondrial metabolism contributes to the platelet
phenotype.
To examine directly mitochondria bioenergetics in 14-3-3z-
deﬁcient platelets, we employed the XFp extracellular ﬂux
analyser, which allows determination of mitochondrial function
through the measurement of oxygen consumption rate (OCR),
in the extracellular milieu of cells. As demonstrated in Fig. 8a–d,
basal OCR in platelets isolated from both genotypes were similar.
We further proﬁled mitochondrial function in both genotypes by
examining OCR following the addition of well-deﬁned inhibitors
of the electron transport chain, including oligomycin, FCCP
(uncoupler) and Rotenone/Antimycin A (Complex I/III). Resting
platelets isolated from either 14-3-3z-wt or 14-3-3z-deﬁcient mice
demonstrated a standard metabolic response to each inhibitor,
with a reduction in OCR on inhibition of F0F1 ATP synthase
(ATP-linked respiration), a rapid increase in OCR on FCCP-
mediated uncoupling of the electron transport chain (maximal
respiration), and ﬁnally a complete inhibition of OCR by
inhibiting complexes I and III (Fig. 8a,b). As with basal OCR,
the rate and extent of OCR in response to all treatments was



















































































































Figure 5 | 14-3-3f-deﬁcient mice are protected from pulmonary thromboembolism. Thromboembolism was induced in 14-3-3z-wt and 14-3-3z-deﬁcient
(14-3-3z-null) mice by intravenous injection of collagen and epinephrine, as described under ‘Methods’. In control studies, mice were injected with saline
(Control). (a) Number (percentage, %) of mice surviving at 10 and 30min post collagen/epinephrine injection, n¼8. (b(i)) Lungs were collected, ﬁxed in
10% formalin and 5mm sections cut from parafﬁn-embedded lung tissue. Sections were stained with Masson Trichrome and analysed for the presence of
thrombi on an Olympus BX51 microscope; images were captured using a DP70 camera and DP70-BSW software (scale bar¼ 100mm). 14-3-3z-wt mice
had extensive occlusive platelet thrombi (yellow arrows), which were signiﬁcantly reduced/absent in surviving 14-3-3z-null mice and absent in all saline
controls. Note: 14-3-3z-wt lung histology derived from a mouse with platelet count¼0 103 ml at time of death 90000 0 ; 14-3-3z-null lung histology derived
from a surviving mouse with platelet count¼ 90 103 ml, taken at 300000 0; (ii) clot burden in the lungs of both 14-3-3z-wt and 14-3-3z-null mice was
assessed by quantiﬁcation of the number of occluded vessels per ﬁeld of view. Saline control images were found to have no occluded vessels. These results
represent the mean±s.e.m. (n¼ 3–4 mice, 3–5 sections imaged per mouse). Results were analysed using an unpaired Student’s t-test, where
****Po0.0001. (c) In vivo thrombin generation was measured in plasma samples taken at 10 and 30min post injection using a thrombin–antithrombin
(TAT) ELISA; n¼4–8 since some mice had already died at early time points post injection. Results were analysed using one-way ANOVA (Bonferroni’s
post hoc), *Po0.05. (d) Blood samples were taken from mice at 10 and 30min post injection and platelet counts were compared with saline controls at the
same time points.
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mitochondrial function in platelets stimulated with potent platelet
agonists, identical measurements were obtained from 14-3-3z-wt
and 14-3-3z-deﬁcient platelets stimulated with a combination
of CRP (0.25mgml 1) and thrombin (0.5 Uml 1). Agonist
stimulation of platelets resulted in an increased ATP-linked
respiration, which was enhanced in 14-3-3z-deﬁcient platelets,
along with a 1.7-fold increase in respiratory reserve capacity
(Fig. 8a,c,d). Similar ﬁndings were demonstrated in human
platelets pretreated with the 14-3-3 dimer destabilizer RB-011
(Supplementary Fig. 6b). These ﬁndings support the notion that
14-3-3z-deﬁcient platelets have an increased capacity for
mitochondrial ATP generation during periods of metabolic stress
induced by potent platelet agonists.
Discussion
Platelets play a key role in propagating coagulation reactions
within a developing thrombus, necessary for efﬁcient thrombus
growth and stability5. This is primarily dependent on their ability
to express negatively charged phospholipids on their plasma
membrane, particularly PS, through mitochondrial-driven cell
death pathways linked to the activation of phospholipid
scramblases26,30. In this manuscript, we describe an important
role for the 14-3-3z adaptor protein in regulating platelet PS
exposure and procoagulant function following potent platelet
activation. This non-redundant role for 14-3-3z is linked to



















































Figure 7 | Oligomycin negates the reduction in PS exposure in
14-3-3f-deﬁcient platelets. Anticoagulated whole blood was isolated from
14-3-3z-wt (black bars) or 14-3-3z-deﬁcient (14-3-3z-null, white bars)
mice. Exposure of PS was quantiﬁed through measurement of
Alexa-488-labelled Annexin V (ANV) (a) and mitochondrial membrane
potential measured by TMRM staining (b), as described under ‘Methods’.
PS and mitochondrial membrane potential were quantiﬁed in the presence
of buffer alone (vehicle) or oligomycin A (1 mM) (oligomycin), following
stimulation of platelets with CRP/thrombin (CRP (0.25 mgml 1)/Thr
(0.5 Uml 1)) or calcium ionophore A23187 (Iono, 1 mm), for the indicated
times. Results are expressed as the mean±s.e.m. (n¼ 8), and analysed
using two-way ANOVA with Bonferroni’s post hoc testing where
****Po0.0001; ***Po0.005; **Po0.01; NSP40.05.




































































Figure 6 | 14-3-3f-deﬁcient platelets demonstrate sustained metabolic
ATP following potent activation. (a) Washed platelets (1 108ml 1)
were isolated from 14-3-3z-wt (black symbols) or 14-3-3z-deﬁcient
(14-3-3z-null) (white symbols). Where indicated (squares), platelets were
pre-incubated with oligomycin (1mM), prior to stimulation. Metabolic ATP
was extracted and quantiﬁed in unstimulated (Resting) and stimulated
platelets with a mix of CRP (0.25mgml 1) and thrombin (0.5Uml 1) for
up to 1,800 s as described in ‘Methods’ section. Results are expressed as
the percentage (%) change in ATP compared with resting control levels
over the indicated times, and represent the mean±s.e.m. (n¼4).
A two-way ANOVA was used to determine statistical difference
between 14-3-3z-wt and 14-3-3z-null platelets (NSP40.05; *Po0.05).
(b,c) Western blot analysis of phospho-AMPK in 14-3-3z-wt and
14-3-3z-null platelets: Washed platelets (3 108ml 1) were isolated from
14-3-3z-wt and 14-3-3z-null mice and activated with CRP/thrombin
(0.25mgml 1, 1 Uml 1). After activation, platelets were lysed using RIPA
buffer. Platelet lysates were analysed by western blot analysis of phospho-
AMPK protein using a phosphospeciﬁc antibody (40H9). The western blot
in b is taken from one representative of three independent experiments.
Total b-actin was used as a loading control, and quantiﬁcation of phospho-
AMPK signal was expressed as a ratio of protein loading (c, mean±s.e.m.,
n¼ 3), using LICOR technology. A Student’s t-test was used to determine
statistical difference between 14-3-3z-wt and 14-3-3z-null platelets
(*Po0.05). Where appropriate, results were analysed using either unpaired
Student’s t-test, two-way ANOVA with Tukey’s post hoc testing.
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altered mitochondrial bioenergetics, with deﬁciency of 14-3-3z
leading to an enhanced capacity to respond to metabolic stress as
a consequence of increased mitochondrial respiratory reserve.
These ﬁndings highlight a new function for 14-3-3 adaptor
proteins in regulating mitochondrial bioenergetics linked to
PS exposure, independent of apoptosis. They also raise the
interesting possibility that therapeutic targeting of platelet
mitochondrial metabolism may represent a new approach to
reduce thrombosis.
Most of the available evidence supporting an important
signalling role for 14-3-3z in platelets relates to GPIba
(refs 10–13,16,18,37–42). This conclusion is partly based on
mutagenesis strategies that have targeted the 14-3-3z binding site
on the C-terminal domain of GPIba (refs 11–13,16,39,41,42).
CHO cells transfected with GPIb mutants that are incapable
of binding 14-3-3z have revealed reduced GPIb-dependent
integrin aIIbb3 activation11,12. Furthermore, studies using a
membrane-permeable phosphorylated peptide inhibitor of the
14-3-3z–GPIba interaction (MPaC) have demonstrated reduced
VWF binding to GPIba and decreased platelet adhesion under
ﬂow conditions13. The interpretation of these studies with respect
to 14-3-3z signalling is complicated by the possibility that these
approaches may have removed the interaction of all 14-3-3
isoforms with GPIba. Mangin et al.18 demonstrated that all
isoforms of 14-3-3 present in platelets have the capacity to bind
GPIba through the same C-terminal GPIb binding domains
utilized by 14-3-3z (residues 580–590 and 606–610). It is likely
that the remaining 14-3-3 isoforms present in platelets are able to
compensate for 14-3-3z deﬁciency and promote GPIb-dependent
integrin aIIbb3 activation.
Much speculation has surrounded the signalling mechanisms
leading to the development of platelet procoagulant function,
with a growing body of evidence supporting a central role for
mitochondrial-driven cell death pathways in this process30. Two
cell death pathways can induce platelet PS exposure and
procoagulant function—programmed cell apoptosis and
regulated cell necrosis26. The former pathway plays a central
role in regulating the lifespan of circulating quiescent platelets43,
which we show here is unaffected in 14-3-3z-deﬁcient platelets.
Interestingly, our own studies using mouse platelets deﬁcient in
the proapoptotic Bcl-2 family proteins Bak and Bax have revealed
that development of activation-dependent PS exposure is
unperturbed, instead demonstrating that necrotic-like cell death
pathways are principally involved in regulating agonist-induced
development of procoagulant platelets26. Cell necrosis is
typically caused by bioenergetic failure of the cell and the
studies presented in this manuscript are consistent with this
concept, demonstrating that reduced platelet PS exposure in
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Figure 8 | 14-3-3f deﬁciency enhances platelet mitochondrial respiratory reserve capacity. Washed platelets were isolated from 14-3-3z-wt
(black circles/bars) or 14-3-3z-deﬁcient (14-3-3z-null, white circles/bars) mice. Mitochondrial respiration was measured in DMEM-modiﬁed media using
the Seahorse XFp analyzer, according to the manufacturer’s instructions. (a) Representative trace identifying the typical pattern of OCR, depicting basal
level, proton leak, ATP production, maximal respiration and reserve capacity, following inhibition of individual electron transport chain complexes (indicated
by arrowheads), including: (1) vehicle or agonist; (2) oligomycin; (3) FCCP; and (4) rotenone/antimycin A. Platelets were assayed for oxygen consumption
in unstimulated (b) or CRP/Thr-stimulated (0.25mgml 1/0.5Uml 1) (c,d) conditions. (d) Reserve capacity in CRP/Thr-stimulated platelets was
calculated based on the difference between the basal and maximal OCR (c). Results represent the mean±s.e.m. (n¼ 8), and were analysed using
two-way ANOVA (Bonferroni’s post hoc), where **Po0.01; *Po0.05.
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14-3-3z-deﬁcient platelets correlates with enhanced mitochondrial
bioenergetic function, sustained levels of metabolic ATP and
reduced AMPK activation. To our knowledge there are no reports
of 14-3-3 adaptor proteins inﬂuencing regulated cell necrosis
pathways linked to bioenergetic function and PS exposure in any
cell type.
Mitochondrial ATP production is important to meet the
increased energy demands of activated platelets33. Direct evidence
that mitochondrial bioenergetics were dysregulated in
14-3-3z-deﬁcient platelets was based on our extracellular ﬂux
analysis, which identiﬁed increased mitochondrial respiratory
reserve capacity in these cells, under activation conditions. This
respiratory reserve capacity is typically required during periods of
metabolic or oxidative stress, as may occur following potent
platelet stimulation. Interestingly, the respiratory reserve capacity
of platelets is relatively low compared with other hemopoietic
cells, representing only 20–30% of total mitochondrial respiratory
function44. It is notable that the regulatory systems controlling
intracellular free calcium levels consume a major portion of the
cell’s energy supply (up to 90%). Thus it is not surprising that
high, sustained calcium levels induced by strong platelet agonists
would be expected to lead to ATP depletion and an eventual
breach of the respiratory reserve, promoting cell death. The
factors regulating the volume of the reserve capacity and its
biological relevance are not well understood. Our ﬁndings
demonstrate for the ﬁrst time the involvement of 14-3-3z in
regulating the mitochondrial reserve capacity, and suggest an
important biological function in the context of platelet
procoagulant function and thrombosis.
Our ﬁndings that oligomycin A can completely eliminate the
impact of 14-3-3z deﬁciency on platelet bioenergetics suggest
that 14-3-3z has a major non-redundant role in regulating
mitochondrial ATP production. In this context, it is interesting to
note that the target of oligomycin, the F0F1 ATP synthase
has been recently implicated as an integral component
of the mitochondrial membrane permeability transition pore
(mPTP)45–48. This is a key structure facilitating permeability
transition and functional decline of mitochondria under
conditions of cellular stress, including elevated calcium, ROS
and ATP depletion. Studies in barley sprouts have identiﬁed a
direct interaction between 14-3-3 proteins and the b-subunit of
the F1 domain of the F0F1 ATP synthase, resulting in
downregulation of enzyme activity, decreasing the generation of
ATP49,50. It is tempting to speculate that the platelet phenotype
observed in 14-3-3z-deﬁcient mice may be due in part to a direct
interaction between 14-3-3z with the F0F1 ATP synthase in
mammalian cells. However, the demonstration of enhanced
respiratory reserve capacity in 14-3-3z-deﬁcient platelets occurs
in the presence of oligomycin (a direct inhibitor of the F0F1 ATP
synthase), suggests that additional 14-3-3 targets may be involved
in regulating mitochondrial bioenergetics.
The demonstration that 14-3-3z deﬁciency in platelets is not
associated with spontaneous or surgical bleeding, yet protects
mice from arterial thrombi, raises the interesting possibility that
therapeutic targeting of 14-3-3z, may represent a safe and
effective antithrombotic strategy. A growing body of evidence
supports the concept that reducing the procoagulant function of
platelets may help reduce propagation of arterial thrombi,
without impacting on haemostasis51,52. 14-3-3z is ubiquitously
expressed and shares a high degree of homology with several
other 14-3-3 isoforms, so the ability to develop isoform-selective
inhibitors with limited toxicity remains a challenge. Nonetheless,
there is growing interest in developing 14-3-3z inhibitors for the
treatment of cancer53,54, since overexpression of 14-3-3z occurs
commonly in cancer53,54, and is associated with disease
recurrence53–55 and resistance to chemotherapy56–58. Many of
the cancers associated with dysregulated 14-3-3z signalling53,
such as stomach, lung, pancreatic, breast, diffuse large B-cell
lymphoma, ovarian and lung have an increased risk of
venous thromboembolism59–61, with fatal pulmonary embolism
representing a signiﬁcant cause of premature death in these
patients62. The demonstration that 14-3-3z deﬁciency protects
from fatal pulmonary embolism in mice raises the interesting
possibility that 14-3-3 inhibitors may have the added beneﬁt of
reducing thrombotic complications during cancer therapy.
Methods
Materials. Antibodies and reagents—rat monoclonal Ab’s Xia.B2 (anti-GPIba),
Xia.G5-FITC (anti-GPIba), Xia.C3-FITC (anti-GPIbb), Leo.F2-FITC (anti-integrin
aIIbb3), JAQ.1-FITC (anti-GPVI) and JonA-PE (anti-activated integrin aIIbb3) were
from Emfret Analytics (Eibelstadt, Germany). Anti-mouse P-selectin-FITC was
from Becton Dickinson. OG-FGN, sulfo-NHS biotin, ADP, calcium ionophore
A23187, probenecid, annexin V and ellagic acid were from Sigma-Aldrich
(St Louis, MO). Anti-Phospho-AMPKa (Thr172) rabbit mAb (40H9), b-Actin
(8H10D10) mouse mAb, antibodies selective for anti-14-3-3 b/a(#9636),
anti-14-3-3 g (#9637), anti-14-3-3 t (#9638) and anti-rabbit IgG HRP-linked
antibody (#7074) were from Cell Signaling Technology (USA); anti-14-3-3z (C-16,
sc-1019) or pan-14-3-3 isoform antibodies (K19, sc-629) were from Santa Cruz
Biotechnology, Inc (USA). Annexin V was ﬂuorescently labelled in house using
Alexa-488 (Molecular Probes, Eugene, OR). IRDye 680LT Donkey anti-Mouse IgG
and IRDye 800CW Donkey anti-Rabbit IgG secondary antibodies were from
LI-COR Biotechnology (Lincoln, USA). Tetramethylrhodamine methyl ester
(TMRM) was from Molecular Probes (Eugene, OR). Thrombin and the thrombin-
anti-thrombin (TAT) ELISA kit were from Dade Behring (Marburg, Germany).
PAR-4 agonist peptide AYPGKF was from Auspep (Parkville, Victoria, Australia).
U46619 was from Merck (Australia). Collagen-related peptide (CRP) was from
Richard Farndale (Oxford, UK). ENLITEN Luciferase/Luciferin reagent was
purchased from Promega (Sydney, Australia). Seahorse Bioscience XF reagents
were purchased from 3 In Vitro Technologies Pty. Ltd (Queensland, Australia).
The 14-3-3 dimer destabilizer RB-011 was synthesized as described previously23.
Commercially available colorimetric enzyme assay kits to quantify pyruvate kinase
(ab83432) and 6-phosphofructokinase (ab155898) activity were purchased from
Abcam (Victoria, Australia). All other reagents were from sources described
previously22,26,63. Working concentrations of all antibodies and reagents used for
each application are speciﬁed in the following speciﬁc method section(s).
Mouse strains. 14-3-3z-deﬁcient mice were generated using gene trap constructs
as described by Cheah et al.19 Animal experiments were conducted in accordance
with the guidelines of SA Pathology and the Central Adelaide Local Health
Network (CALHN) and University of Sydney Animal Ethics Committees,
according to ethics applications E/0475/2006/M and E/0936/2010/M approved by
the Alfred Medical Research & Education Precinct Animal Ethics Committee, and
ethics application 2014/620 approved by the University of Sydney Animal Ethics
Committee. Platelet counts were performed on a Sysmex KX-21N automated
haematology analyser (Roche Diagnostics, Australia) using sub-mandibular blood
samples collected into EDTA tubes.
Generation of 14-3-3f bone marrow-transplanted mice. Sv129 (14-3-3z-wt and
14-3-3z-null) female mice of at least 8 weeks of age were irradiated with 1,200 cGy
using a deep X-ray irradiation machine. Irradiated mice were transplanted with
intravenous injections of 15 106 bone marrow cells, collected from tibiae and
femurs from male (14-3-3z-wt and 14-3-3z-deﬁcient) mice, resuspended in
phosphate-buffered saline (PBS). Volumes for injections were 0.5ml per
transfusion. The percentage of male marrow in total host marrow cells was
determined at 8 weeks post transplant using ﬂuorescent in situ hybridization
(FISH) probing for the presence of the Y-chromosome. The FISH probe was
prepared as reported by Donnelly and colleagues64, wherein a Y-chromosome
probe was produced using degenerate oligonucleotide primed-PCR
(oligonucleotide—CCGACTCGAGNNNNNNATGTGG) with a template
derived from murine Y-chromosome.
Determination of platelet lifespan. Mice were injected intravenously (tail vein)
with 600 mg sulpho-NHS biotin. At 4 h post injection and time points thereafter,
blood was collected from the tail vein and the percentage of CD41-positive events
that were streptavidin-PE positive was quantitated by ﬂow cytometry43.
Flow cytometry. Anti-coagulated whole blood samples were diluted 1:20 in
Tyrode’s buffer65. For receptor expression analysis, samples were stained with
ﬂuorophore-conjugated monoclonal antibodies for 10min at room temperature
and analysed on a FACSCalibur ﬂow cytometer (BD Biosciences).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12862 ARTICLE
NATURE COMMUNICATIONS | 7:12862 | DOI: 10.1038/ncomms12862 | www.nature.com/naturecommunications 11
VWF binding. Washed mouse platelets (2 107ml 1) in Tyrode’s buffer65
supplemented with 1% BSA were incubated with Alexa488-VWF (1–20 mgml 1)
in the presence or absence of the VWF-modulator botrocetin (10mgml 1) for
30min at room temperature, then diluted to 400 ml and analysed immediately
by ﬂow cytometry. Results are expressed as VWF:GPIba binding ratio using
Xia.G5-FITC mAb (5 ml mAb stock solution in 25ml total assay volume),
according to the manufacturer’s instructions, to measure GPIba expression levels
on 14-3-3z-wt and 14-3-3z-deﬁcient platelets.
P-selectin expression and integrin aIIbb3 activation. Diluted mouse blood
samples were pre-incubated with either rat anti-mouse P-selectin-FITC Ab
(1mgml 1), or JON/A-PE (5ml stock solution in 25ml total assay volume)
according to the manufacturer’s instructions. Washed human platelets
(1 108ml 1) were incubated with anti-PAC-1-FITC monoclonal antibody
(0.25 mgml 1, BD biosciences). Samples were stimulated with various agonists for
the indicated times at 37 C, diluted with Tyrode’s buffer and analysed by ﬂow
cytometry.
Measurement of Annexin V binding. Washed mouse platelets (5.0 107ml 1)
were incubated with CRP or thrombin (either alone or in combination (CRP/Thr)),
at the indicated doses, calcium ionophore A23187 (0.25–1.0 mM) or ABT-737
(1mM) for 30–60min (where indicated) in the presence of Alexa488-Annexin V
(1–2 mgml 1). Samples were diluted into Tyrode’s buffer and analysed
immediately by ﬂow cytometry.
Measurement of mitochondrial membrane potential. Washed mouse platelets
(1 108ml 1) in PWB were incubated with TMRM (0.5 mM) for 15min at 37 C.
Excess TMRM was then removed by centrifugation and platelets resuspended in
Tyrode’s buffer. Samples were incubated with a combination of CRP and
Thrombin (CRP/Thr) at the indicated doses or calcium ionophore A23187 (1 mM)
for 10–30min (where indicated). Samples were diluted into Tyrode’s buffer and
analysed immediately by ﬂow cytometry.
Static adhesion. Glass coverslips were coated with 50 mgml 1 human VWF in
BSA-free Tyrode’s buffer overnight at 4 C and blocked with 2% (w/v) BSA for 1 h
at room temperature. Washed mouse platelets (2 107ml 1), were allowed to
adhere at 37 C in the presence of 10 mgml 1 botrocetin. Platelet adhesion was
imaged by DIC microscopy (Leica DMIRB, water immersion objective:
 63, numerical aperture: 1.2) and images captured using DVT tools (Pinnacle
Systems, USA).
Platelet aggregation. Washed mouse platelets (2 108ml 1) were resuspended
in Tyrode’s buffer. All aggregation studies65 were initiated by addition of the
indicated concentrations of adenosine diphosphate (ADP) or CRP to platelet
suspensions stirred at 600 r.p.m. for 10min at 37 C in a four-channel automated
platelet analyser (AggRAM, Helena Laboratories, Tyne and Wear, UK) in the
presence of 1mM calcium and 0.5mgml 1 ﬁbrinogen. The extent of platelet
aggregation was deﬁned as the percentage change in optical density as measured by
the automated platelet analyser.
Quantiﬁcation of activated partial thromboplastin time. Activated partial
thromboplastin time (APTT) was quantiﬁed in a puriﬁed system using ellagic acid
as a contact pathway activator and a deﬁned number of washed platelets as a source
of phospholipid. Brieﬂy, platelet-poor plasma (PPP) was prepared from citrate-
anticoagulated whole blood, centrifuged at 2,000g for 10min to separate plasma
from blood cells. In a ﬁnal assay volume of 300ml, PPP (100 ml), ellagic acid
(0.1mM ﬁnal) and assay buffer (50mM Hepes, 25mM Tris, pH 7.35) were
pre-warmed (37 C) prior to addition to a glass cuvette. Washed human or mouse
platelets (resting or activated with CRP/TRAP or CRP/PAR4-AP; 0.5 mgml 1
CRP; 1.0 mM TRAP; 200 mM PAR4-AP) were added and the assay mixture
incubated at 37 C for 2min. Calcium (25mM) was ﬁnally added to initiate
coagulation and APTT measured as the time taken from addition of calcium to the
formation of a clot, measured visually by the detection of ﬁbrin strands. In control
studies, addition of excess annexin V (100 mgml 1) to the assay prior to initiation
of coagulation completely prevented the formation of ﬁbrin. Results were expressed
as fold difference over the APTT obtained from control (vehicle-treated human or
14-3-3zþ /þ mouse) platelets.
Extracellular ﬂux analysis of platelet metabolic function. The mitochondrial
and glycolytic function of isolated platelets was determined through real-time
measurement of OCR and ECAR, respectively, using the XFp Extracellular Flux
Analyzer (Seahorse Bioscience, MA, USA), according to the manufacturer’s
instructions. Brieﬂy, washed platelets (400 106ml 1) were resuspended in
Dulbecco’s Modiﬁed Eagle’s Medium (assay medium, Sigma, D5030) containing
Hepes (0.02M, pH 7.35; ICN Biomedicals INC) and apyrase (0.02Uml 1).
In some experiments, washed platelets were pretreated with vehicle or RB-011
(10 mM). Platelets (20 106 per 200ml) were then loaded into XFp microplate
wells, and maintained at 37 C for 30min, prior to equilibration. For measurement
of OCR, assay medium was supplemented with glucose (2.5M), pyruvate (1mM)
and glutamine (1mM). OCR was quantiﬁed following consecutive treatment of
platelets with four different treatments: (1) assay medium alone (resting) or a mix
of CRP (0.25mgml 1) and thrombin (0.5Uml 1) (stimulated); (2) oligomycin
(1 mM); (3) FCCP (1mM); and (4) rotenone (5 mM) and antimycin A (5mM). For
measurement of ECAR, assay medium was supplemented with Glutamine (1mM),
and ECAR quantiﬁed in platelets consecutively treated with (1) assay medium
(resting) or a mix of CRP (0.25 mgml 1) and thrombin (0.5 Uml 1; stimulated);
(2) glucose (1M); (3) oligomycin (1 mM); and (4) 2-DG (1M). For each assay, ﬁve
individual basal measurements were taken, followed by consecutive injection of
treatments. Three measurements were recorded after each injection, with each
measurement consisting of 10 s mixing and 3min measurement period.
Measurement of metabolic intraplatelet ATP. To quantify intraplatelet
metabolic ATP levels, both total intraplatelet ATP as well as metabolically inert
ATP sequestered in platelet granules66 was quantiﬁed, using a modiﬁed luciferase
assay67. Washed mouse platelets (1 108ml 1) were stimulated with CRP
(0.25 mgml 1) and thrombin (0.5 Uml 1) for the indicated times under stirring
conditions at 37 C. In some experiments, washed platelets were pretreated with
vehicle or RB-011 (10 mM), prior to stimulation. Assays were stopped at the
completion of each time point by the addition of 0.1M EDTA, pH 7.4. The
supernatant containing granular ATP and the pellet containing metabolic ATP
were separated via centrifugation. ATP from both fractions was extracted by
addition of an ice cold 0.1M EDTA:Ethanol (9:1) solution containing 1.5M NaCl,
pH 7.4, and separated by centrifugation (13,000 r.p.m., 10min, 4 C). A volume of
100 ml of the resultant supernatant was mixed with tris-acetate buffer (0.1M, 2mM
EDTA, pH 7.75). ATP content was measured by mixing 10 ml of supernatant with
50 ml luciferase/luciferin reagent and luminescence quantiﬁed on a ﬂuorescence
plate reader (BMG FLUOstar OPTIMA). The ATP content was then calculated
using values obtained from an ATP standard curve, and expressed as percentage of
control.
Measurement of glycolytic enzyme activity. Pyruvate kinase (PK) and
6-phosphofructokinase (6-PFK) activity enzyme activities were quantiﬁed from
platelet lysates using commercially available colorimetric assay kits (Abcam,
Victoria, Australia) according to the manufacturer’s instructions, and quantiﬁed
using an Inﬁnite M1000 Pro micro-plate reader (Tecan, Victoria, Australia).
Brieﬂy, washed platelets resuspended in Tyrode’s buffer (1 108ml 1) were
treated with buffer alone (resting) or a combination of CRP (0.25 mgml 1) and
Thrombin (0.5Uml 1) (CRPþThr) for the indicated time periods, followed by
the addition of assay-speciﬁc extraction buffer. A volume of 10 ml of lysate was
diluted with the provided assay buffer, combined with reaction mix and kinetics of
enzyme activity quantiﬁed over 30min (25 and 37 C) at 570 and 450 nm, for PK
and 6-PFK, respectively.
Coimmunoprecipitation of GPIba and 14-3-3f. Resting platelet whole-cell lysates
were prepared using RIPA buffer65 containing protease (cOmplete) and
phosphatase inhibitor (PhosSTOP) cocktails (Roche, Germany). GPIba was
immunoprecipitated from whole-cell lysates (0.2–0.5mg) using Xia-B2 monoclonal
antibody or isotype-matched control immunoglobin G (5 mg) for 1 h, followed by
addition of 20ml protein A/G Plus overnight at 4 C. SDS–polyacrylamide gel
electrophoresis (PAGE) and immunoblot analysis were performed26,68, following
GPIba immunoprecipitation, whereby samples were mixed with SDS sample buffer
in the presence of 0.1M dithiothreitol, and heated to 95 C for 5min. Equal protein
concentration for each sample were subjected to SDS–PAGE on standard 12.5%
(v/v) polyacrylamide gel, transferred to polyvinylidene diﬂuoride (PVDF) and
probed for GPIb with RAM-6 mAb (1mgml 1; ref. 69) or anti pan-14-3-3 pAb
(0.2 mgml 1), followed by horseradish peroxidase (HRP)-conjugated secondary
antibody (1:10,000 from the stock solution) and enhanced chemiluminescence.
SDS–PAGE and western blotting. Resting platelet whole-cell lysates were
prepared as described above. For each sample, equal protein was separated by
migration on either standard 12.5% (v/v) polyacrylamide gel (for examination of
Phospho-AMPK), or Bio-Rad Criterion XT pre-cast gels (4–12% Bis-Tris; for
examination of 14-3-3 isoform expression). Separated proteins were transferred to
PVDF membrane and immunoblotted with either Phospho-AMPK (1:1,000),
b-actin (1:1,000), 14-3-3a/b (1:1,000), 14-3-3g (1:1,000), 14-3-3t (1:1,000) and
14-3-3z (0.4 mgml 1) primary antibodies, followed by incubation with either
anti-rabbit IgG HRP-conjugated secondary antibody70 (1:10,000) and enhanced
chemiluminescence, for examination of 14-3-3 isoform expression, or IRDye
680LT Donkey anti-Mouse IgG (0.2 mgml 1) and IRDye 800CW Donkey
anti-Rabbit IgG (0.2 mgml 1) secondary antibodies for the examination of b-actin
and Phospho-AMPK, respectively. Quantiﬁcation was performed using either a
BIORAD ChemiDoc MP 3304 imager (Bio-Rad Laboratories, New South Wales,
Australia) or an Odyssey CLx Imager (Li-Cor Biotechnology, Millennium Science,
Australia). Original uncropped immunoblots have been provided in
Supplementary Fig. 8.
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In vitro ﬂow-based thrombus formation. Glass microslides were coated with
Type I ﬁbrillar collagen (250 mgml 1). Hirudin-anticoagulated whole blood was
perfused at 1,800 s 1 and thrombus formation was monitored for 5min. Adherent
platelets and thrombi were observed using a Leica DMIRB microscope (Leica
Microsystems, Wetzlar, Germany) and DIC microscopy ( 63, 1.2W objective).
Data were recorded onto DVD for ofﬂine analysis using Metamorph (Molecular
Devices, CA) or ImageJ software (National Institutes of Health).
Tail bleeding time. A 3mm tail-tip transection method was used to assess hae-
mostasis in 20–25 g male and female anaesthetized and ventilated mice22.
Following transection, the mouse tail was immediately immersed into warmed
(37 C) saline. The bleeding time was determined as the time from the tail
transection to the moment the blood ﬂow stopped for more than 120 s. A bleeding
time beyond 30min was considered as the cutoff time for the purpose of statistical
analysis. Red blood cells were pelleted and lysed in 1ml H20. Haemoglobin was
quantiﬁed by absorbance at 575 nm (Beckman DU530 Life Science UV/Vis
Spectrophotometer). Following cessation of bleeding, the incision was monitored
for a further 120 s, and further bleeding within this period classiﬁed as ‘re-bleeding’.
The duration of rebleeding was monitored as described above. Non-genotyped
mice were used for the 3mm tail-tip assay, and were subsequently genotyped using
tail tissue collected post euthanasia.
Electrolytic model of thrombosis. Electrolytic injury of the carotid artery20 was
performed using 14-3-3z-deﬁcient, 14-3-3z-wt litter mates and bone marrow-
transplanted mice, where indicated. Mice were anaesthetized with sodium
pentobarbitone (60mg kg 1), and body temperature was monitored/maintained at
37 C throughout the experiment (using both a heat lamp and thermoblanket
(Harvard Apparatus Ltd, Kent, UK). Following surgical exposure of carotid
arteries, a calibrated ﬂow probe (0.5mm i.d.) linked to a ﬂow meter (TS420,
Transonic Systems Inc., Ithaca, NY, USA) was placed around the left carotid artery
to measure blood ﬂow velocity (in mlmin 1, ﬁnally corrected for body weight
(mlmin 1 per 100 g)). After 10min of stable blood ﬂow, a hook-shaped electrode
was placed around the left carotid artery, distal to the ﬂow probe. Blood stasis was
created by clamping the left carotid artery, and vascular injury induced by
delivering an electrical current (18mA, 2min). Following removal of the clamp,
changes in blood ﬂow were monitored for 60min and recorded for ofﬂine analysis
using PowerLab LabChart 6 software (ADInstruments, New South Wales,
Australia). The total amount of blood ﬂowing through the injured artery following
vascular injury was determined by calculating the area under the blood ﬂow curve
using Prism software (Version 5.01, Graphpad). Patency time cumulative time
during 60min measurement period that vessel remained open (blood
ﬂow40mlmin 1) and time to ﬁrst occlusion (blood ﬂowr0mlmin 1) were also
analysed. The effect of 14-3-3z deﬁciency on stability of blood ﬂow post injury was
classiﬁed into three categories: no blood blow (black bar), unstable blood ﬂow
(white bar) and stable blood ﬂow (hatched bar). Note: no blood ﬂow was
characterized by occlusion of the carotid artery post injury, with no return of blood
ﬂow in the 60min post injury observation period. Unstable blood ﬂow was
characterized either by periods of arterial occlusion, followed by periods of
returned blood ﬂow, or blood ﬂow that did not occlude but rather demonstrated
patterns of decreasing and increasing ﬂow, denoting partial thrombus formation
and embolization, respectively. Stable blood ﬂow was characterized by a complete
return of blood ﬂow post injury, with no occlusion or ﬂuctuations in the ﬂow.
Thromboembolism induced by collagen and epinephrine. A mixture of
1.0mg kg 1 Type I ﬁbrillar collagen and 60mg kg 1 epinephrine were injected
into the jugular vein of anaesthetized mice. Blood samples were taken at 10 and
30min post injection for determination of platelet count and to measure thrombin/
anti-thrombin (TAT) complexes22 as a measure of thrombin generation. Mice were
monitored for time of death and lungs were collected, ﬁxed in 10% formalin, and
5 mm sections cut from parafﬁn-embedded lung tissue. Sections were stained with
Masson Trichrome and analysed for the presence of thrombi on an Olympus BX51
microscope; images were captured using a DP70 camera and DP70-BSW software
(Olympus) ( 20 magniﬁcation).
Statistical analysis. Statistical signiﬁcance between treatment groups was
analysed using either a one- or two-way ANOVA (with Boneforroni’s, Sidak’s
or Tukey’s post hoc testing, as recommended) or an unpaired Student’s t-test
with two-tailed P values (Prism software; GraphPAD Software for Science,
San Diego, CA), as indicated. Data are presented as means±s.e.m., where ‘n’
equals the number of independent experiments performed.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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